Peer-Reviewed Research Reveals a 74% Drop in Excess Mortality with Ivermectin Use
In the midst of the COVID-19 pandemic, the search for effective treatments has been ongoing. One drug that has sparked controversy and debate is Ivermectin. Recently, a peer-reviewed study from Peru has shed new light on the effectiveness of Ivermectin in reducing COVID-19-related deaths.
Ivermectin, a drug commonly used to treat parasitic infections in humans and animals, has gained attention as a potential treatment for COVID-19. Early on, advocates such as Dr. Pierre Kory championed the use of Ivermectin, citing promising results from preliminary studies. However, detractors raised concerns about the lack of rigorous peer review, dismissing the drug as "horse medicine." But now, with the publication of a peer-reviewed study from Peru, the effectiveness of Ivermectin in reducing COVID-19 deaths has been vindicated.
The study in question focused on the impact of Ivermectin on excess COVID-19 deaths across Peru's 25 states in 2020. Different regions implemented varying degrees of Ivermectin distribution, with some states distributing maximum doses, others adopting a moderate approach, and a few limiting its distribution. The findings were astonishing: states with the most intensive Ivermectin use observed an average reduction of 74% in excess deaths within 30 days after the peak death rate.
This correlation between Ivermectin use and decreased mortality rates was further reinforced when the new Peru presidential administration limited the drug's use. Following this restriction, there was a notable rise in the death rate, undoing the progress made with Ivermectin. Before the restriction, Peru experienced a significant reduction in nationwide excess deaths, but this was followed by a sharp increase in the months that followed. This study provides additional evidence that Ivermectin indeed played a crucial role in reducing COVID-19 deaths.
The acceptance of this study in a renowned scientific journal marks a turning point in the conversation surrounding Ivermectin. The once-dismissed preprint now holds substantial weight in the scientific community. It challenges the previous skepticism and highlights the potential of Ivermectin as a valuable tool in the fight against COVID-19. The findings from Peru provide a strong case for further exploration and consideration of Ivermectin's use in COVID-19 treatment protocols.
The timing of the study's publication, after a significant portion of the population has developed natural immunity and as mass vaccination rates decrease, raises questions about the intentions and actions of regulatory authorities. Dr. McCullough has reported that approximately 97% of Americans have already acquired natural immunity, offering robust protection against COVID-19. Additionally, the FDA's recent admission that doctors can freely prescribe Ivermectin for COVID-19 adds to the suspicion surrounding the delay in recognizing its effectiveness. These circumstances prompt further investigation into the motivations behind such decisions.
The publication of this study on Ivermectin's effectiveness in reducing COVID-19 deaths serves as a reminder of the importance of rigorous scientific research and the need to remain open-minded to potential treatments. It highlights the significance of peer review in validating scientific findings and emphasizes the role of evidence-based medicine in shaping public health policies.
As the pandemic continues, it is crucial to prioritize research and exploration of potential treatments. The study from Peru provides valuable insights into the impact of Ivermectin, but further research is needed to fully understand its mechanisms of action, optimal dosage, and potential side effects. Collaboration between researchers, healthcare professionals, and regulatory authorities is essential to make informed decisions and develop effective strategies in the battle against COVID-19.